Quick Answer
A JAMA Pediatrics study of 204,000 teens shows GLP-1 drugs now account for 96% of obesity treatment in ages 13-25 in the US, replacing bariatric surgery. Indian parents of overweight children and teens should know what GLP-1 therapy means for young patients and when it is appropriate.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
A major new study published in JAMA Pediatrics on July 20, 2026 has confirmed what doctors treating adolescent obesity have been observing for the past two years: GLP-1 receptor agonist drugs like Ozempic and Wegovy have essentially replaced bariatric surgery as the dominant treatment for obesity in teenagers and young adults. For Indian parents who are concerned about their child's weight and wondering what options are available, this shift in global medical practice carries significant implications.
What the Study Found
Researchers at UT Southwestern Medical Center in Dallas analyzed health records from more than 204,000 young people aged 13 to 25 who were treated for obesity between May 2022 and January 2026, using the Epic Cosmos database — one of the largest electronic health record systems in the United States. The findings were dramatic. Exclusive GLP-1 drug use among this age group rose from 88.2 percent in 2022 to 96.1 percent in early 2026. Over the same period, metabolic and bariatric surgery rates fell from 11.6 percent to just 3.7 percent. The two treatments in combination remained stable at around 0.2 percent throughout. In practical terms, the study shows that GLP-1 drugs have largely displaced surgery as the first-line treatment for adolescent obesity within a span of just three years. The researchers noted this is a significant shift and called for clearer evidence-based guidance on how these drugs should be used long-term in younger patients.
Why This Happened
The shift reflects both the dramatic efficacy of GLP-1 drugs and the considerable barriers to adolescent bariatric surgery. Surgery requires general anaesthesia, a hospital stay, and a long recovery. It carries risks of nutritional deficiencies, dumping syndrome, and psychological adjustment challenges that are particularly significant in growing teenagers. Many families and doctors were reluctant to choose surgery as a first option for a 13 or 15 year old when alternatives existed. GLP-1 drugs, by contrast, produce meaningful weight loss — averaging 10 to 16 percent of body weight over a year on semaglutide, and 15 to 20 percent on tirzepatide — with a side effect profile that is largely manageable and reversible. When combined with dietary guidance and exercise, these results are genuinely transformative for many young patients.
In the United States, the FDA approved semaglutide (Wegovy) for adolescents aged 12 and above in December 2022, and tirzepatide (Zepbound) for the same age group in November 2024. This regulatory clarity gave paediatricians and endocrinologists a defined framework for prescribing — and prescriptions followed rapidly.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The India Context: A Growing Crisis That Parents Cannot Ignore
India is facing a childhood obesity crisis that deserves far more public attention than it currently receives. According to data from the Indian Council of Medical Research, the prevalence of overweight and obesity among children and adolescents aged 5 to 19 years has risen sharply over the past two decades, driven by ultra-processed food consumption, sedentary screen time, and increasingly urban lifestyles. Some estimates suggest that more than 14 percent of urban Indian teenagers are now overweight or obese, with the figure higher still in metros like Delhi, Mumbai, and Bengaluru.
Childhood and adolescent obesity is not simply a cosmetic concern. It dramatically increases the risk of type 2 diabetes, polycystic ovary syndrome, fatty liver disease, high blood pressure, and orthopedic problems in later life. Young people who are obese in their teenage years are significantly more likely to remain obese as adults, and significantly more likely to die prematurely from cardiovascular disease. The health consequences of untreated adolescent obesity in India will compound over the coming decades as this generation ages.
Where India Currently Stands on GLP-1 for Adolescents
India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved semaglutide for type 2 diabetes management in adults, and the drug is available both as branded Ozempic and in generic form from multiple Indian manufacturers. However, semaglutide for weight management in adolescents has not yet received a dedicated paediatric label approval in India, unlike in the United States where the FDA approved Wegovy for ages 12 and above.
This does not mean GLP-1 therapy is unavailable for Indian teenagers — doctors can and do prescribe medications off-label when the clinical evidence strongly supports it and when no approved alternative exists. For adolescents with severe obesity and significant metabolic complications such as diabetes or fatty liver disease, a paediatric endocrinologist or bariatric physician may consider GLP-1 therapy appropriate even in the absence of a specific paediatric label. This is a nuanced clinical decision that must be made individually and by a qualified specialist.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
What the Evidence Says About Safety in Young Patients
The side effect profile of GLP-1 drugs in adolescents is broadly similar to adults: nausea, vomiting, and diarrhoea in the early weeks of dose escalation, which typically resolve as the body adapts. The STEP TEENS trial, the pivotal randomised study that supported the FDA approval of semaglutide in adolescents, followed 201 teenagers aged 12 to 17 for 68 weeks and found average weight loss of 16.1 percent in the semaglutide group versus a weight gain of 0.6 percent in the placebo group. No new safety signals were identified beyond those seen in adults. Muscle loss is a concern with all weight-loss interventions in growing teenagers, which is why protein intake and resistance exercise are emphasised alongside GLP-1 therapy in young patients.
Long-term data in adolescents remains limited — GLP-1 drugs have only been used in this age group at scale since 2023. This is an honest limitation. The full picture of how these drugs affect bone density, reproductive development, and metabolism over a decade of use in teenagers will only become clear as the cohorts grow up. Parents should weigh this uncertainty honestly, but also weigh it against the well-documented harms of untreated severe obesity in adolescence.
What Indian Parents Should Do
If your child or teenager is significantly overweight and standard lifestyle interventions — dietary changes, reduced screen time, regular physical activity — have not produced results over 6 to 12 months of genuine effort, a referral to a paediatric endocrinologist or a specialist trained in adolescent metabolic health is the right next step. Do not wait until obesity is severe, because early intervention produces better outcomes. Be sceptical of informal online sources selling GLP-1 products for children — dosing, monitoring, and support for young patients require specialist supervision, and incorrect use can be harmful.
A GLP-1 specialist at MySurgery can advise on whether GLP-1 therapy is clinically appropriate for your child, what dose escalation looks like for adolescents, what monitoring is needed, and what the realistic weight loss trajectory would be. We work with families, not just individual patients.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. UT Southwestern Medical Center — GLP-1 use rising rapidly among U.S. adolescents, young adults — https://www.utsouthwestern.edu/newsroom/articles/year-2026/july-glp-1-adolescents.html 2. US News and World Report — GLP-1 Use Surges Among Young People With Obesity — https://www.usnews.com/news/health-news/articles/2026-07-22/glp-1-use-surges-among-young-people-with-obesity 3. AJMC — GLP-1 Use in Youth Climbs as Bariatric Surgery Rates Fall — https://www.ajmc.com/view/glp-1-use-in-youth-climbs-as-bariatric-surgery-rates-fall
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.